美敦力旗下糖尿病业务MiniMed(MMED.US)提交IPO申请，拟募资至多1亿美元

智通财经2025-12-22

智通财经APP获悉，上周五，美敦力(MDT.US)旗下专注于糖尿病管理设备与技术的业务分拆实体——MiniMed，正式向美国证券交易委员会提交了相关文件，拟通过首次公开募股(IPO)的方式募集不超过1亿美元的资金。MiniMed计划以股票代码“MMED”在纳斯达克证券交易所挂牌上市。此次交易中，高盛、美银证券、花旗以及摩根士丹利将共同担任联合簿记管理人。不过，目前具体的定价条款尚未对外披露。这一...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2593100184?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-22 16:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593100184","market":"fut","top_or_hot":-1,"title":"美敦力旗下糖尿病业务MiniMed(MMED.US)提交IPO申请，拟募资至多1亿美元","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，上周五，美敦力(MDT.US)旗下专注于糖尿病管理设备与技术的业务分拆实体——MiniMed，正式向美国证券交易委员会提交了相关文件，拟通过首次公开募股(IPO)的方式募集不超过1亿美元的资金。MiniMed计划以股票代码“MMED”在纳斯达克证券交易所挂牌上市。此次交易中，高盛、美银证券、花旗以及摩根士丹利将共同担任联合簿记管理人。不过，目前具体的定价条款尚未对外披露。这一...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1384371.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美敦力旗下糖尿病业务MiniMed(MMED.US)提交IPO申请，拟募资至多1亿美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美敦力旗下糖尿病业务MiniMed(MMED.US)提交IPO申请，拟募资至多1亿美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-22 16:29 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1384371.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，上周五，美敦力(MDT.US)旗下专注于糖尿病管理设备与技术的业务分拆实体——MiniMed，正式向美国证券交易委员会提交了相关文件，拟通过首次公开募股(IPO)的方式募集不超过1亿美元的资金。MiniMed计划以股票代码“MMED”在纳斯达克证券交易所挂牌上市。此次交易中，高盛、美银证券、花旗以及摩根士丹利将共同担任联合簿记管理人。不过，目前具体的定价条款尚未对外披露。这一...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1384371.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0122379950.USD","symbol_name":"贝莱德世界健康科学A2","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1384371.html","article_id":"2593100184","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593100184","pubTimestamp":1766392165,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，上周五，美敦力旗下专注于糖尿病管理设备与技术的业务分拆实体——MiniMed，正式向美国证券交易委员会提交了相关文件，拟通过首次公开募股的方式募集不超过1亿美元的资金。MiniMed计划以股票代码“MMED”在纳斯达克证券交易所挂牌上市。从宣布计划到提交申请，美敦力糖尿病业务的独立之路按部就班推进。在2025财年，美敦力糖尿病业务销售额为27.5亿美元，仅占公司总营收336.3亿美元的8%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0122379950.USD":"贝莱德世界健康科学A2","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","IE00BQXX3F31.USD":"GUINNESS GLOBAL INNOVATORS \"C\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","BK4588":"碎股","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","BK4585":"ETF&股票定投概念","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","BK4566":"资本集团","IE00BQXX3C00.GBP":"GUINNESS GLOBAL INNOVATORS \"C\" (GBP) ACC","IE00BQXX3D17.EUR":"GUINNESS GLOBAL INNOVATORS \"C\" (EUR) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","MDT":"美敦力","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC"},"translate_title":"Medtronic's diabetes business MiniMed (MMED.US) submitted an IPO application to raise up to US $100 million","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDT":1.5},"content_text":"智通财经APP获悉，上周五，美敦力(MDT.US)旗下专注于糖尿病管理设备与技术的业务分拆实体——MiniMed，正式向美国证券交易委员会提交了相关文件，拟通过首次公开募股(IPO)的方式募集不超过1亿美元的资金。MiniMed计划以股票代码“MMED”在纳斯达克证券交易所挂牌上市。此次交易中，高盛、美银证券、花旗以及摩根士丹利将共同担任联合簿记管理人。不过，目前具体的定价条款尚未对外披露。这一动作标志着这项拥有40年历史的糖尿病护理业务，正式启动独立上市进程。此次拆分始于2025年5月美敦力公布的战略调整，计划在未来18个月内完成全部分离，最终打造“更专注的美敦力”与独立运营的糖尿病科技企业双主体格局。从宣布计划到提交申请，美敦力糖尿病业务的独立之路按部就班推进。在9月初的摩根士丹利全球医疗保健会议上，美敦力管理层曾表示，糖尿病业务的IPO预计将在2026年初进行，分拆则会在IPO完成后约六个月进行。然而，根据12月19日的最新消息，这一进程似乎比预期更快。美敦力表示，IPO预计将在完成美国证券交易委员会审查流程后启动，具体时间取决于市场及其他相关条件。财务数据显示，在截至2025年10月24日的六个月中，MiniMed报告的净销售额为14.8亿美元，净亏损2100万美元;相较去年同期13.0亿美元的净销售额和2300万美元的净亏损，营收有所增长而亏损略有收窄。作为从美敦力分拆而出的公司，MiniMed 专注于糖尿病综合管理，产品涵盖胰岛素输送设备、持续血糖监测仪(CGM)、输注器、储药器、笔式系统及相关软件与服务。截至 2025 年 10 月，公司胰岛素泵用户超过 64 万人;在截至 2025 年 10 月 24 日的六个月内，其 CGM 搭载率达 65%，上一周期为 58%。约 83% 的总收入来自 CGM、其他耗材、软件和服务，体现了持续销售模式的稳定性。新公司总部仍将设立在加利福尼亚州北岭，拥有8000多名员工。在2025财年，美敦力糖尿病业务销售额为27.5亿美元，仅占公司总营收336.3亿美元的8%。虽然该业务在2025财年实现了10.7%的营收增长，但仅贡献了公司分部营业利润的4%。分拆后，美敦力预计整体调整后毛利率将提高50个基点，营业利润率将提高100个基点。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593100184","isCrawlerRequest":true}